Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy raises £10mln at a premium

The fundraising is led by Paris-based DNCA Investments which is investing £4.8mln; small change for a company with more than £23bn assets under management
harley street
The new shares will represent 12.8% of the enlarged share capital of the company

Advanced Oncotherapy PLC (LON:AVO) is raising £10.0mln as it presses ahead with the building of its next-generation LIGHT proton therapy system on Harley Street.

Investors taking part in the fundraising, including Paris-based DNCA Investments, are paying 40p a share – an 11% premium to Thursday’s closing price.

READ: AVO improves performance of LIGHT system

As well as funding the continued development of the first LIGHT system, the money will also pay for software development and costs relating to the new testing and assembly site being set up at a science park in Cheshire.

In its last stock exchange announcement in October, AVO announced it had doubled the power of the proton beam in the LIGHT system.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Related Articles

glasshouse
January 08 2019
Its plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use